DICP OpenIR
Saxagliptin alters bile acid profiles and yields metabolic benefits in drug-naive overweight or obese type 2 diabetes patient
Li, Wen1,2; Liu, Ruixin1,2; Li, Xuelin1,2; Tao, Bei1,2; Zhai, Nan1,2; Wang, Xiaolin3; Li, Qi3; Zhang, Yifei1,2; Gu, Weiqiong1,2; Wang, Weiqing1,2; Ning, Guang1,2,4,5
Corresponding AuthorWang, Weiqing(wqingw61@163.com)
Keywordbile acids dipeptidyl peptidase-4 inhibitor obesity saxagliptin type 2 diabetes
Source PublicationJOURNAL OF DIABETES
2019-07-29
ISSN1753-0393
DOI10.1111/1753-0407.12956
Pages11
Funding ProjectNational Key R&D Program of China[2018YFC1314800] ; Chinese National Natural Science Foundation[81730023] ; Shanghai Municipal Education Commission - Gaofeng Clinical Medicine Grant Support[20161403]
Funding OrganizationNational Key R&D Program of China ; National Key R&D Program of China ; Chinese National Natural Science Foundation ; Chinese National Natural Science Foundation ; Shanghai Municipal Education Commission - Gaofeng Clinical Medicine Grant Support ; Shanghai Municipal Education Commission - Gaofeng Clinical Medicine Grant Support ; National Key R&D Program of China ; National Key R&D Program of China ; Chinese National Natural Science Foundation ; Chinese National Natural Science Foundation ; Shanghai Municipal Education Commission - Gaofeng Clinical Medicine Grant Support ; Shanghai Municipal Education Commission - Gaofeng Clinical Medicine Grant Support ; National Key R&D Program of China ; National Key R&D Program of China ; Chinese National Natural Science Foundation ; Chinese National Natural Science Foundation ; Shanghai Municipal Education Commission - Gaofeng Clinical Medicine Grant Support ; Shanghai Municipal Education Commission - Gaofeng Clinical Medicine Grant Support ; National Key R&D Program of China ; National Key R&D Program of China ; Chinese National Natural Science Foundation ; Chinese National Natural Science Foundation ; Shanghai Municipal Education Commission - Gaofeng Clinical Medicine Grant Support ; Shanghai Municipal Education Commission - Gaofeng Clinical Medicine Grant Support
WOS SubjectEndocrinology & Metabolism
WOS Research AreaEndocrinology & Metabolism
WOS KeywordDIPEPTIDYL PEPTIDASE-4 INHIBITORS ; Y GASTRIC BYPASS ; INSULIN-RESISTANCE ; GUT MICROBIOME ; FATTY LIVER ; WEIGHT-LOSS ; RECEPTOR ; METFORMIN ; IDENTIFICATION ; INFLAMMATION
AbstractBackground The aim of the present study was to investigate the metabolic benefits of saxagliptin and its effects on serum bile acids (BAs) in normal weight and overweight/obese drug-naive type 2 diabetes (T2D) patients. Methods In all, 282 drug-naive T2D patients (123 normal weight [NW], with body mass index [BMI] between 19.0 and <25.0 kg/m(2); 159 overweight/obese [OW/OB], with BMI >= 25.0 kg/m(2)) were enrolled in the study and treated with saxagliptin 5 mg daily for 24 weeks. Serum BAs were assayed by liquid chromatography with tandem mass spectrometry. Results At 24 weeks, HbA1c was significantly reduced in both groups, but the HbA1c levels were lower in the OW/OB than NW group. Moreover, significant decreases were seen at 24 weeks in C-reactive protein (CRP), aspartate aminotransferase, alanine aminotransferase, waist circumference, and systolic blood pressure in the OW/OB group. Interestingly, cholic acid, glycocholic acid, glycochenodeoxycholic acid, glycodeoxycholic acid (GDCA), and glycoursodeoxycholic acid (GUDCA) were increased in both groups after treatment, whereas chenodeoxycholic acid and deoxycholic acid (DCA) were specifically increased in the OW/OB group. Increased DCA and GDCA concentrations were significantly associated with decreased HbA1c or fasting blood glucose and CRP levels, whereas increased GDCA and GUDCA concentrations were associated with decreased waist circumference in the OW/OB group during treatment. In the NW group, increased GUDCA concentrations were significantly associated with a decrease in HbA1c. Conclusions Type 2 diabetes patients with OW/OB exhibited greater improvement in glycemic control and additional metabolic benefits after saxagliptin treatment. Saxagliptin significantly increased the BA pool, and DCA and GDCA were associated with metabolic improvements in OW/OB T2D patients.
Language英语
Funding OrganizationNational Key R&D Program of China ; National Key R&D Program of China ; Chinese National Natural Science Foundation ; Chinese National Natural Science Foundation ; Shanghai Municipal Education Commission - Gaofeng Clinical Medicine Grant Support ; Shanghai Municipal Education Commission - Gaofeng Clinical Medicine Grant Support ; National Key R&D Program of China ; National Key R&D Program of China ; Chinese National Natural Science Foundation ; Chinese National Natural Science Foundation ; Shanghai Municipal Education Commission - Gaofeng Clinical Medicine Grant Support ; Shanghai Municipal Education Commission - Gaofeng Clinical Medicine Grant Support ; National Key R&D Program of China ; National Key R&D Program of China ; Chinese National Natural Science Foundation ; Chinese National Natural Science Foundation ; Shanghai Municipal Education Commission - Gaofeng Clinical Medicine Grant Support ; Shanghai Municipal Education Commission - Gaofeng Clinical Medicine Grant Support ; National Key R&D Program of China ; National Key R&D Program of China ; Chinese National Natural Science Foundation ; Chinese National Natural Science Foundation ; Shanghai Municipal Education Commission - Gaofeng Clinical Medicine Grant Support ; Shanghai Municipal Education Commission - Gaofeng Clinical Medicine Grant Support
WOS IDWOS:000481367900001
PublisherWILEY
Citation statistics
Document Type期刊论文
Identifierhttp://cas-ir.dicp.ac.cn/handle/321008/173558
Collection中国科学院大连化学物理研究所
Corresponding AuthorWang, Weiqing
Affiliation1.Shanghai Jiao Tong Univ, Dept Endocrine & Metab Dis,Ruijin Hosp, Shanghai Key Lab Endocrine Tumours,Shanghai Clin, Shanghai Inst Endocrine & Metab Dis,Sch Med, Shanghai, Peoples R China
2.Shanghai Inst Endocrinol, Shanghai, Peoples R China
3.Chinese Acad Sci, Key Lab Separat Sci Analyt Chem, Dalian Inst Chem Phys, Dalian, Peoples R China
4.Chinese Acad Sci, Lab Endocrinol & Metab, Inst Hlth Sci, Shanghai Inst Biol Sci, Shanghai, Peoples R China
5.Shanghai Jiao Tong Univ, Sch Med, Shanghai, Peoples R China
Recommended Citation
GB/T 7714
Li, Wen,Liu, Ruixin,Li, Xuelin,et al. Saxagliptin alters bile acid profiles and yields metabolic benefits in drug-naive overweight or obese type 2 diabetes patient[J]. JOURNAL OF DIABETES,2019:11.
APA Li, Wen.,Liu, Ruixin.,Li, Xuelin.,Tao, Bei.,Zhai, Nan.,...&Ning, Guang.(2019).Saxagliptin alters bile acid profiles and yields metabolic benefits in drug-naive overweight or obese type 2 diabetes patient.JOURNAL OF DIABETES,11.
MLA Li, Wen,et al."Saxagliptin alters bile acid profiles and yields metabolic benefits in drug-naive overweight or obese type 2 diabetes patient".JOURNAL OF DIABETES (2019):11.
Files in This Item:
There are no files associated with this item.
Related Services
Recommend this item
Bookmark
Usage statistics
Export to Endnote
Google Scholar
Similar articles in Google Scholar
[Li, Wen]'s Articles
[Liu, Ruixin]'s Articles
[Li, Xuelin]'s Articles
Baidu academic
Similar articles in Baidu academic
[Li, Wen]'s Articles
[Liu, Ruixin]'s Articles
[Li, Xuelin]'s Articles
Bing Scholar
Similar articles in Bing Scholar
[Li, Wen]'s Articles
[Liu, Ruixin]'s Articles
[Li, Xuelin]'s Articles
Terms of Use
No data!
Social Bookmark/Share
All comments (0)
No comment.
 

Items in the repository are protected by copyright, with all rights reserved, unless otherwise indicated.